"Eli Lilly reported Q1 2026 revenue of $19.80 billion, up 55.5% year over year, with non-GAAP EPS of $8.55 versus a $6.79 consensus. Net income of $7.40 billion roughly doubled, and management raised full-year revenue guidance to $82.0 billion to $85.0 billion."
"Mounjaro generated $8.66 billion in quarterly revenue, up 125%, fueled by international expansion, including the addition to China's National Reimbursed Drug List."
"Foundayo launched fast, with 20,000 prescriptions in the first 20 days, and 80% of those patients were new to GLP-1s, indicating a significant expansion of the category."
"Hershey management described chocolate as 'an emotional category' and 'a treat, not a meal,' suggesting that while core confections are insulated, growth is occurring at the edges of the portfolio."
Eli Lilly controls 60% of the GLP-1 market, with Q1 2026 revenue reaching $19.80 billion, a 55.5% increase year over year. Mounjaro generated $8.66 billion in quarterly revenue, up 125%, aided by international expansion. Foundayo, a new oral GLP-1, quickly gained traction with 20,000 prescriptions in its first 20 days. Hershey is adapting to market changes, emphasizing that chocolate remains an emotional category while growth is seen in newer product lines.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]